Key result
Intensive remote management leaves ~31% of high-risk patients with device-detected AF unanticoagulated.
Why the study?
The burden of remote monitoring AF alerts and its impact on anticoagulation in patients with device-detected AF needed characterization.
Cohort (n=7,651)
Yes
Despite intensive remote monitoring and automated prompts, a substantial proportion of high-risk patients with device-detected AF remain unanticoagulated, highlighting a gap in clinical response pathways.
Answers are grounded in this paper and cite their sources.
Persistent anticoagulation gaps in high-risk device-detected AF persist despite remote monitoring; leaves open optimal implementation strategies for prospective study.
Background Remote monitoring (RM) can facilitate early detection of subclinical and symptomatic atrial fibrillation (AF), providing an opportunity to evaluate the need for stroke prevention therapies. We aimed to characterize the burden of RM AF alerts and its impact on anticoagulation of patients with device-detected AF. Methods Consecutive patients with a cardiac implantable electronic device, at least one AF episode, undergoing RM were included and assigned an estimated minimum CHA 2 DS 2 -VASc score based on age and device type. RM was provided via automated software system, providing rapid alert processing by device specialists and systematic, recurrent prompts for anticoagulation. Results From 7651 individual, 389,188 AF episodes were identified, 3120 (40.8%) permanent pacemakers, 2260 (29.5%) implantable loop recorders (ILRs), 987 (12.9%) implantable cardioverter defibrillators, 968 (12.7%) cardiac resynchronization therapy (CRT) defibrillators, and 316 (4.1%) CRT pacemakers. ILRs transmitted 48.8% of all AF episodes. At twelve-months, 3404 (44.5%) AF < 6 min, 1367 (17.9%) 6 min–6 h, 1206 (15.8%) 6–24 h, and 1674 (21.9%) ≥ 24 h. A minimum CHA 2 DS 2 -VASc score of 2 was assigned to 1704 (63.1%) of the patients with an AF episode of ≥ 6 h, 531 (31.2%) who were not anticoagulated at 12-months, and 1031 (61.6%) patients with an AF episode duration of ≥ 24 h, 290 (28.1%) were not anticoagulated. Conclusions Despite being intensively managed via RM software system incorporating cues for anticoagulation, a substantial proportion of patients with increased stroke risk remained unanticoagulated after a device-detected AF episode of significant duration. These data highlight the need for improved clinical response pathways and an integrated care approach to RM. Trial registration Australian New Zealand Clinical Trial Registry: ACTRN12620001232921.
No takes yet. Share an insight, caveat, or question.
O’Shea et al. (2023) conducted a cohort in Device-detected atrial fibrillation (n=7,651). Remote monitoring with automated software system was evaluated on Unanticoagulated status at 12 months in patients with AF episode ≥ 6 hours and minimum CHA2DS2-VASc score of 2. Despite intensive management via a remote monitoring software system, 31.2% of patients with a device-detected atrial fibrillation episode of ≥6 hours and a minimum CHA2DS2-VASc score of 2 remained unanticoagulated.
Synapse has enriched 10 related papers. Consider them for comparative context: